Quantcast

Latest Pharmaceutical sciences Stories

2014-09-03 08:34:15

SAN DIEGO, Sept. 3, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Halozyme's program investigating PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with gemcitabine and nab-paclitaxel for the treatment of patients with metastatic pancreatic cancer to demonstrate an improvement in overall survival. The Fast Track designation process was developed...

2014-09-03 08:34:10

Company CEO to present at both the Rodman & Renshaw Global Investment Conference and Aegis Capital 2014 Healthcare and Technology Conference in September JERUSALEM, September 3, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com [http://c/Users/Aviva - Oramed/EFN Synced Tool/.CORPORATE/Public Relations/PressReleases/Press Releases/2014/NEW RELEASES - checking/www.oramed.com ] ), a clinical-stage pharmaceutical company focused on the...

2014-09-03 08:34:03

Features more than 70 in-house counsel, judges, government officials and industry experts in product liability litigation NEW YORK, Sept. 3, 2014 /PRNewswire/ -- American Conference Institute (ACI) is pleased to announce the agenda for its 19(th) Annual Drug and Medical Device Litigation on December 8-10 in New York City. Agenda is now available online. Photo - http://photos.prnewswire.com/prnh/20140903/142346 Featuring 3 new Co-Chairs: Sonia Arnold Counsel-Litigation and Legal Compliance,...

2014-09-03 08:33:57

SEATTLE and VANCOUVER, British Columbia, Sept. 3, 2014 /PRNewswire/ -- CMC Biologics, Inc., a global leader in process development and contract manufacturing, and Zymeworks Inc., a Canadian biotherapeutics company and a world leader in the development of antibody therapeutics, have entered into a Master Services Agreement for process development, formulation development and cGMP clinical manufacturing of a recombinant human IgG1 bi-specific (heterodimeric) antibody....

2014-09-03 08:33:44

Experienced Financial and Operational Leader to Support Global Development of Novel Monoclonal Antibody Therapeutics to GPCRs LA JOLLA, Calif. and SHANGHAI, Sept. 3, 2014 /PRNewswire/ -- RuiYi, Inc., a global therapeutic innovation leader, announced today the appointment of Mark Saad as chief financial officer (CFO). Mr. Saad is a skilled financial and operations leader and was most recently CFO at Cytori Therapeutics for the past ten years. At RuiYi, he will play a critical...

2014-09-03 08:33:04

WOODCLIFF LAKE, N.J., Sept. 3, 2014 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has entered into an agreement with Concordia Pharmaceuticals Inc. ("Concordia"), a subsidiary of Concordia Healthcare Corp., to purchase Eisai's U.S. and Puerto Rican commercialization and distribution rights to Zonegran. As part of the deal terms, Eisai will receive full payment from Concordia upon closing. In addition, Eisai and Concordia are...

2014-09-03 08:32:21

SAN DIEGO, Sept. 3, 2014 /PRNewswire/ -- Ajinomoto Althea, Inc. ("Althea"), a leading provider of biopharmaceutical contract development and manufacturing services announced today that it has officially received its European GMP certificate issued by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA conducted an on-site inspection on June 19, 2014 that yielded no critical or major observations. This certification provides clearance to Althea to test commercial...

2014-09-03 04:21:58

VIENNA, September 3, 2014 /PRNewswire/ -- New US Subsidiary to be located in the Philadelphia Area Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative pathogens, today announced the appointment of Dr Colin Broom as Chief Executive Officer (CEO). Current CEO Ralf Schmid will remain a member of the...

2014-09-02 23:07:10

Dr. Benlhabib has developed cutting-edge methods to formulate modern-day solutions to hair loss based on traditional medicinal plant therapy. Moroccan Eco-Biologics seek support for Indiegogo campaign to conduct clinical trials to gain FDA approval for their products. St. Paul, MN (PRWEB) September 02, 2014 Moroccan Eco-Biologics’ new one-of-a-kind Vitality Hair Recovery products have been refined and specially formulated, while preserving the foundation of all natural Moroccan plant...

2014-09-02 23:03:28

REMIND-A-CAP™ will help the 50% of Americans who do not follow their physician's orders when taking prescription medicine while reducing some of the $290 billion spent each year in avoidable medical expenses attributed to non-adherence New York, NY (PRWEB) September 02, 2014 A New York City based company is focused on addressing the non-adherence epidemic with a simple, yet revolutionary, product that will have far-reaching, positive effects including increasing life span and...


Latest Pharmaceutical sciences Reference Libraries

Phytotherapy Research
2012-05-01 10:17:25

Phytotherapy Research is a monthly peer-reviewed scientific journal publishing original research papers, short communications, reviews, and letters on medicinal plant research. Topics include pharmacology, toxicology, and the clinical applications of herbs and natural products in medicine, from case histories to clinical trials, including studies of herb-drug interactions and other aspects of the safety of herbal medicines. Short communications dealing with the pharmacology and screening...

More Articles (1 articles) »
Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related